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TGFb ligands act as tumor suppressors in early stage
tumors but are paradoxically diverted into potent
prometastatic factors in advanced cancers. The
molecular nature of this switch remains enigmatic.
Here, we show that TGFb-dependent cell migration,
invasion and metastasis are empowered by mutant-
p53 and opposed by p63. Mechanistically, TGFb
acts in concert with oncogenic Ras and mutant-p53
to induce the assembly of a mutant-p53/p63 protein
complex inwhichSmadsserveasessential platforms.
Within this ternary complex, p63 functions are antag-
onized. Downstream of p63, we identified two candi-
date metastasis suppressor genes associated with
metastasis risk in a large cohort of breast cancer
patients. Thus, two common oncogenic lesions,
mutant-p53 and Ras, selected in early neoplasms
to promote growth and survival, also prefigure
a cellular set-up with particular metastasis proclivity
by TGFb-dependent inhibition of p63 function.
INTRODUCTION
Cancer progression is amultistep process involving the accumu-
lation of genetic and epigenetic changes in several genes. Still,
how distinct defects cooperate to generate a metastatic tumor
remains a long-standing unanswered question in cancer biology.
The fact that specific gene-sets, or signatures, already
expressed in primary tumors have been found predictive for
metastasis, has led to the proposal that metastatic proclivity
might be intimately wired to the same aberrant genetic pathways
that control tumorigenesis in the primary tumor (Bernards and
Weinberg, 2002).One of the most frequent genetic lesions in human tumors is
mutation of the p53 tumor suppressor, which acts as transcrip-
tion factor to promote cytostasis, apoptosis and genome integ-
rity. More than 80% of p53 alterations are missense mutations
that lead to the synthesis of a stable but transcriptionally
deficient protein (Soussi and Beroud, 2001). Why do tumor cells
retain a disabled tumor suppressor, rather than losing it for
good? An important step in answering this question has been
the generation of mutant-p53 knockin mice (Lang et al., 2004;
Olive et al., 2004). Remarkably, tumors emerging in thesemodels
display aggressive and metastatic traits that are never detected
in tumors developing in a p53 null background. This is supported
by molecular epidemiology data in humans, showing that
mutant-p53 expressing tumors are aggressive and associated
to poor-prognosis (Sorlie et al., 2001; Soussi and Beroud, 2001).
Intriguingly, activating mutations in the Ras signaling pathway
appear critical for the malignant phenotypes of mutant-p53
(Caulin et al., 2007; Hingorani et al., 2005). Thus, p53 mutation,
in concert with oncogenic Ras, leads to a gain of molecularly
undefined properties that render mutant-p53 a dominant prom-
etastatic factor. Whether this entails the intersection with other
pathways involved in neoplastic transformation is unknown.
TGFb/Smad signaling plays a central role for tumorigenesis of
several epithelia, paradoxically switching from tumor suppressor
to promoter of metastasis during cancer progression (Derynck
et al., 2001). Here we present evidence of a TGFb-initiated intra-
cellular cascade specifically relevant in advanced tumor cells for
metastasis. We show that mutant-p53 expression is required for
sustaining TGFb proinvasive responses and metastatic spread
in vivo. Moreover, we shed light on the enigmatic nature of the
prometastatic switches of mutant-p53 and TGFb by showing
that these converge on the same mechanism: Ras-activated
mutant-p53 and TGFb conspire to oppose the activity of the
p53 family member p63. p63 is a master gene for normal epithe-
lial stem cells, protecting them from apoptosis and coordinating
their differentiation (Deyoung and Ellisen, 2007). Here we showCell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc. 87
Figure 1. Mutant-p53 Expression Promotes TGFb Promigratory Responses
(A) Schematic representation of our starting hypothesis.
(B) Western blot of H1299 cell lysates: parental, i.e., lacking p53 expression (null), reconstituted with wild-type p53 (p53 wt) or mutant-p53 (p53 R175H). Lamin-B
is a loading control. Control RNA levels are shown in Figure S1B.
(C) Effect of TGFb (5 ng/ml of TGFb for 24 hr) on the morphology of H1299 cells.
(D) Wound healing assays of H1299 cells showing effect the mutant-p53 on TGFb-driven migration (pictures taken after 30 hr).
(E) H1299 cells were seeded on transwell membranes. Where indicated, cells were treated with TGFb. The graphs show the number of cells migrated through
the transwell after 16 hr. Data are represented as mean and SD.a role for p63 in metastasis protection that is disabled by the
quantitative physical incorporation of p63 into a ternary protein
complex together with mutant-p53 and TGFb activated Smads.
Finally, we also unveiled, and functionally validated, two genes
regulated by this pathway that may be used as efficient prog-
nostic tool in clinical settings.
RESULTS
Mutant-p53, but Not Wild-Type p53, Empowers a TGFb
Promigratory Response
We sought to compare the effects of wild-type and mutant-p53
on the cellular response to TGFb (Figure 1A). To this end, we
used p53 null H1299 cells stably reconstituted with inducible
expression vectors coding for wild-type human p53 or the
hot-spot p53R175H mutant allele. The two cell populations
expressed p53 proteins at similar levels and retained similar
responsiveness to TGFb, as judged by activation of P-Smad3
and of a synthetic reporter of Smad activity (pCAGA12-lux)
(Figure 1B and Figure S1A available with this article online).
In agreement with previous findings, reconstitution of H1299
cells with wild-type p53 rescued the ability of TGFb to induce88 Cell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc.p21WAF1 and growth arrest (Figure 1B and data not shown, see
Cordenonsi et al., 2007). In contrast, reconstitution with mutant-
p53 was ineffective in this respect (Figure 1B). TGFb treatment
of H1299 cells bearing p53R175H caused instead a strikingly
different phenotype, as cells shed their cuboidal epithelial shape
and acquired a moremesenchymal phenotype, characterized by
a number of dynamic protrusions, such as filopodia and lamelli-
podia (Figure 1C). These were not present in parental cells or in
cells reconstituted with wild-type p53 (Figure 1C and data not
shown). To examine if expression of mutant-p53 also conferred
migratoryproperties to cells receivingTGFb,weusedawounding
assay, in which cells are induced tomigrate into awound created
by scratching confluent cultures with a pipette tip. After TGFb
treatment,while parental (p53 null) or wild-type p53 reconstituted
H1299 cells had migrated poorly, p53R175H expressing cells
almost completely invaded the wound (Figure 1D and data not
shown). As an independent mean of measuring cell motility, we
also carried out transwell-migration assays. Figure 1E shows
that expression of mutant-p53, but not of wild-type p53, parallels
with the acquisition of a TGFb promigratory response.
These data establish p53 as the only known Smad regulator
whose mutational status can impart two profoundly different
Figure 2. Mutant-p53 Is Required for TGFb-Driven Invasion
and Metastasis in Breast Cancer MDA-MB-231 Cells
(A) Transwell assay for TGFb dependent migration of MDA-MB-231
cell lines. TGFb was used at 5 ng/ml. This response depends on
canonical Smad signaling, as attested by blockade of migration
ensuing Smad4 depletion (compare lanes 1 and 2 and see also
Figure S2B). Endogenous mutant-p53 is required for this response
as validated by two independent siRNA sequences (A and B, respec-
tively, lanes 3 and 4). The sequence corresponding to siRNA-B was
cloned in pSUPER-Retro and used for stable p53 interference. We
tested the whole population of positive transfectants (lane 6) or two
independent clones (lanes 7 and 8). TGFb-dependent migration of
clone 2 is rescued by infection with a lentiviral vector coding for
siRNA-resistant mutant-p53 (R175H, lane 9). Controls for p53 and
Smad4 depletions are shown in Figure S2A. Data are represented
as mean and SD.
(B and C) SCID mice were injected in the fat pad with MDA shGFP or
MDA shp53 cells. (B) The rate of primary tumor growth was similar
between the two cell populations. Data are represented as mean
and SD (C) Number of mice scored positive for lymphonodal metas-
tasis. To quantify metastatic spread, we monitored the colonization
of controlateral lymph nodes, a read-out of systemic disease in human
breast cancers (Sobin and Wittekind, 2002).
(D, E, and F) Lung colonization assays after tail vein injection of
MDA-MB-231 cell lines (1 3 106 cells/mouse). (D) Total number of
lung metastatic nodules in individual mice was counted on serial
histological sections. Lane 1: control (shGFP) cells (n = 20). Lane 2:
canonical Smad signaling is required for MDA-MB-231 lung metas-
tasis as revealed by the inhibitory effect of Smad4 depletion (n = 9).
Lanes 3 and 4: impaired metastasis in two independent shp53 clonal
cell lines (clone 1 and 2, siRNA sequence B, see Figure 2A). Clone1,
n = 10; clone 2, n = 21. Similar result was obtained by depletion of
mutant-p53 with siRNA sequence A (Figure S2E). Lanes 5 and 6: effect
of reconstitution with wild-type (n = 10) and mutant-p53 (R175H,
n = 12). Panels show representative immunohistochemistry for human
cytokeratin in sections of lungs from mice injected with MDA shGFP
(E) or MDA shp53 (F). Data are represented as mean and SD.interpretations to TGFb signal, being able to switch the cellular
responses from tumor suppressive, supported by wild-type
p53 (Cordenonsi et al., 2003, 2007), to promalignant, promoted
by mutant-p53.
Mutant-p53 Is Required for TGFb-Driven Invasion
and Metastasis in Breast Cancer Cells
Our data link the gain of mutant-p53 to TGFb induced epithelial
plasticity and migration, phenotypes whose emergence is
critical for TGFb invasive properties (Derynck et al., 2001).
However, the actual requirement for these effects of mutant-
p53 endogenously expressed in metastatic cancer cells re-
mained a key unanswered issue. To address this, we knocked
down endogenous mutant-p53 (p53R280K, Table S1) in MDA-
MB-231 cells, a well-established model of invasive breast
cancer. In transwell-migration assays, TGFb triggered a Smad-
dependent promigratory response in these cells (Figures 2A
and S2B). Remarkably, this response was lost in mutant-p53-
depleted cells (Figure 2A). Once embedded in a drop of Matrigel,
MDA-MB-231 cells display a TGFb dependent scattering, extra-cellular matrix degradation and migration (Figures S2C and
S2D), recapitulating in vivo invasiveness. We found that
mutant-p53 expression is required for these activities. These
data suggest that, at least in vitro, mutant-p53 and TGFb jointly
control cell shape and invasiveness of breast cancer cells.
Multiple evidences indicate that the metastatic spread of
MDA-MB-231 cells in vivo is under control of autocrine TGFb
(Table S1). To test if mutant-p53 is relevant for TGFb promoted
malignant behaviors in vivo, we injected control (shGFP) or
stably mutant-p53 depleted (shp53) MDA-MB-231 cells into
the mammary fat pad of immunocompromized mice. The two
cell populations grew at similar rate in vitro (data not shown) and
formed primary tumors at similar rates and size in vivo (Fig-
ure 2B), indicating that high levels of mutant-p53 in MDA-MB-
231 cells are not essential for proliferation or primary tumor
formation. Six weeks after implantation, mice were sacrificed
and examined for presence of metastatic lesions. Orthotopically
injected MDA-MB-231 are poorly metastatic to the lung, but
efficiently metastasize to the lymph nodes. Strikingly, depletion
of mutant-p53 drastically reduced the number of lymph nodeCell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc. 89
metastases when compared to the control cells, as only one out
of 22 mice injected with the shGFP cells scored negative for lym-
phonodal metastasis, whereas 10 out of 22 of mice carrying the
shp53-depleted tumors remained metastasis-free (Figure 2C).
To confirm these results implicating mutant-p53 in invasive-
ness in vivo, we injected control and shp53-MDA-MB-231
intravenously into nude mice. Mutant-p53 is required for lung
colonization, as two independent clones of shp53-MDA-MB-
231 cells displayed overt reduction of metastatic nodules in
number and size (Figures 2D–2F). While control cells massively
invaded the lung parenchyma, small nodules of shp53-cells
remained confined perivascularly (Figure S2F). As specificity
control, metastatic behavior of shp53-MDA-MB-231 cells is
rescued by adding back siRNA insensitive mutant-p53, but not
wild-type p53 (Figure 2D, compare lanes 4, 5, and 6).
Taken together, the data suggest that mutant-p53 expression
plays a crucial role in canalizing TGFb responsiveness for effi-
cient metastatic spread.
p63 Is Downstream of Mutant-p53 and Opposes
TGFb-Induced Malignant Responses
Knockin mice expressing mutant-p53 (p53+/R172H or p53+/
R270H) develop metastatic carcinomas, a phenotype never
observed in mice simply lacking one p53 allele (p53+/) (Lang
et al., 2004; Olive et al., 2004). Intriguingly, loss of one allele of
p63 or p73 similarly endows p53+/ tumors with metastatic
properties (Flores et al., 2005). The parallel between loss of
p63/p73 and gain of mutant-p53 is compatible with mutant-p53
acting as a restraining factor for the activity of its familymembers.
Interestingly, loss of p63 or p73 fosters progression, but in
distinct tumor spectra, with loss of p63 specifically promoting
the emergence ofmetastatic cancers in stratified epithelia (Flores
et al., 2005), that is, tumor types characterized by a clear proma-
lignant-switch in TGFb responses (Derynck et al., 2001).
These hints prompted us to test the role of p63 in cell migration
and invasion induced by TGFb. Transient transfection of p63
(both TA or DNp63a isoforms) caused a marked inhibition of
TGFb-induced transwell migration (Figure 3A). Conversely,
siRNA-mediated depletion of p63 in parental H1299 cells
empowers TGFb-induced migration, phenocopying gain of
mutant-p53 (Figure 3B). We then tested the epistatic relation-
ships between mutant-p53 and p63. Crucially, loss of p63 leads
to a remarkable rescue of TGFb promigratory and proinvasive
properties in p53-depleted MDA-MB-231 cells (Figure 3C,
lanes 3 and 4). To functionally support this notion in vivo, we
stably antagonized endogenous p63 activity using a dominant-
negative protein, termed p63DD, consisting of EGFP fused in
frame with the p63 tetramerization domain (Figures S4A and
S4B). We used a lentiviral delivery system to stably introduce
p63DD in shp53 MDA-MB-231 cells. Remarkably, p63 inactiva-
tion substantially rescues lung colonization in mutant-p53-
depleted cells (Figure 3E). Taken together, the evidences
in vitro and in vivo suggest that TGFb uses mutant-p53 to
surpass the barrier that p63 raises against TGFb-induced malig-
nant cell responses (Figure 3D).
If p63 inhibition by mutant-p53 and TGFb allows the exploita-
tion of TGFb proinvasive properties in metastatic cells, then
experimental downregulation of p63 in non-invasive tumors90 Cell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc.might unleash a TGFb-dependent transition toward more
aggressive cell phenotypes. To test this, we used non-invasive
skin squamous carcinoma B9 cells (Oft et al., 2002). After trans-
fection of p63-siRNA, B9 cells displayed loss of epithelial and
gain of mesenchymal traits (Figures 3F–3H). This shift was
inhibited by blocking TGFb receptor I activity with SB431542,
indicating the reliance on endogenous TGFb signaling. To inves-
tigate the role of p63 in vivo, we stably transduced p63DD in B9
cells and, as a control, in H11 aggressive spindle cells (express-
ing extremely low levels of p63, data not shown). Cells bearing
p63DD or only GFP (as control) were injected sub-cutaneously
into nude mice, and their growth as xenograft tumors was
observed. While expression of p63DD had little effect on tumor
growth and morphology of H11 cells (data not shown), tumors
emerging from p63DD engineered B9 cells displayed an acceler-
ated growth, decreased differentiation and acquisition of a
spindle phenotype with increased stromal invasion (Figures 3I
and 3J).
A TGFb- and Ras-Dependent Ternary Complex
We next sought to address the mechanism by which TGFb
controls p63 through mutant-p53. Previous work has shown
that, at the biochemical level, the recombinant core domain of
some mutant-p53 proteins, but not of wild-type p53, binds and
inhibits p63 by masking its DNA binding domain (Gaiddon
et al., 2001; Strano et al., 2002). However, several observations
suggest that this biochemical model is an oversimplification, that
misses at least one essential component. Indeed, to be effective
as an antagonist, mutant-p53 should be able to quantitatively
titrate p63; in contrast, there is scant evidence that such interac-
tion can effectively occur in vivo at physiological concentrations
of these proteins (Caulin et al., 2007, and see below). Moreover,
stratified epithelia almost exclusively express DNp63, an isoform
per se unable to complex mutant-p53 (Gaiddon et al., 2001).
We tested if Smadsmight be themissing link betweenmutant-
p53 and p63 inactivation. For this, we first immunoprecipitated
endogenous mutant-p53 from HACAT keratinocytes (carrying
the p53H179Y/R282W mutations, Table S1). Co-precipitating
proteins were revealed by Western blotting. In lysates of
untreated cells we could detect only a weak interaction between
p63 and mutant-p53, but this association was massively
augmented in the presence of TGFb signaling (by more than
20-fold; Figure 4A, compare lanes 2 and 3). Crucially, endoge-
nous Smads are essential for mutant-p53/p63 complex
formation, becoming this undetectable upon transfection of
siRNA against Smad2/3 (Figure 4A, compare lane 3 and 4).
These findings suggest that TGFb signaling is an essential deter-
minant for mutant-p53 to complex its family member p63. In an
alternative experimental set-up, coimmunoprecipitation using
anti-Smad2 antibodies reveals Smad2 associated with p63
and mutant-p53 (Figure 4B); yet, while the interaction of
Smad2 with p63 is to a large extent independent from mutant-
p53 (Figure 4B, lane 3), Smad binding to mutant-p53 requires
p63 (Figure 4B, lane 4), suggesting thatmutant-p53 preferentially
associates to a preassembled p63/Smad2 scaffold in these
cells. Together, these biochemical data indicate the formation
of a TGFb-induced ternary complex between endogenous p63,
mutant-p53 and Smads.
Figure 3. p63 Opposes TGFb-Driven Migration
(A) Transwell assay of MDA-MB-231 transiently transfected
with the indicated p63 expression vectors. p63 expression
levels are shown in Figure S3A. Data are represented as
mean and SD.
(B) Loss of p63 confers migratory abilities to H1299 cells in
response to TGFb, phenocopying the gain of mutant-p53.
Graphs show quantification of cells migrated into a defined
wound area 24 hr after cell scraping. Data are represented
as mean and SD.
(C) Transwell migration assay of MDA-MB-231 after transfec-
tion of indicated siRNAs. TGFb induced migration is impaired
by loss of mutant-p53, but is rescued in cells with dual deple-
tion of both p53 and p63. The experiment was repeated in
matrigel-coated transwell filters to monitor invasiveness
(Figure S3C). Similar results were obtained using an siRNA
targeting a different region of p63 mRNA (Figure S3D). The
efficiency of p53 and p63 depletion is shown in Figure S3B.
Note that once p63 is depleted, mutant-p53 becomes
dispensable - and TGFb proficient - for induction of cell migra-
tion (see diagram in [D]). Figure S4C provides independent
evidences for this epistasis by using a p63 dominant-inhibitor,
p63DD. Data are represented as mean and SD.
(D) Model of the epistatic relationships between TGFb,
mutant-p53 and p63.
(E) Functional inactivation of p63 by overexpression of
p63DD in shp53MDA-MB-231 clone 2 (as in Figure 2D)
rescues lung metastastic colonization in tail vein assays
(n = 8, 1 3 106 cells/mouse). Data are represented as mean
and SD.
(F, G, andH)Morphology of B9 squamous cell carcinoma 48 hr
after the indicated siRNA transfection. Note that control cells
form an epithelial monolayer (F) whereas p63 depletion leads
to a mesenchymal morphology (G); similar results were ob-
tained by overexpression of p63DD (data not shown). This
phenotype can be reverted by treatment with SB431542 (H)
and is primed by exogenous TGFb (data not shown). Efficacy
of p63 depletion is shown in Figure S4D.
(I and J) Representative hematoxylin-eosin stainings on
paraffin sections of tumors resulting after subcutaneous injec-
tion of engineered B9 cells. While control (GFP-transduced)
cells formed well-differentiated tumors with keratin pearls (I),
p63-DD expressing tumors were less differentiated and
acquired invasive traits (J).A wealth of evidence in cancer cells and animal models clearly
indicates that metastasis requires the combination of elevated
TGFb and Ras signaling, but the mechanisms of this intersection
remain unclear (Grunert et al., 2003). Interestingly, we previously
showed that the same pathways are involved in mesoderm
development in Xenopus embryogenesis: in that case, however,
it is wild-type p53 that serves as link between Smad and RTK
signaling (Cordenonsi et al., 2007). These precedents prompted
us to test if oncogenic Ras may feed on mutant-p53 for the
formation of the ternary complex. We first wished to address
this in a cellular context free from the multiple genetic changes
that typically characterize cancer cell lines. For this, we used
MEFs derived from p53/ and p53R172H knockin mice, trans-
duced with control or oncogenic HRas-expressing retroviral
vectors (Lang et al., 2004). As shown in Figure 4C, TGFb induced
the formation of the ternary complex between p63, mutant-p53
and Smads only in presence of oncogenic Ras (lane 4). Consis-
tently, TGFb promoted migration of MEFs in transwell assaysonly in cells expressing both mutant-p53 and oncogenic Ras
(Figure 4D).
We previously showed that Ras promotes the formation of
a complex between wild-type p53 and Smads by triggering
phosphorylation the p53 N-terminus through CK13/d kinases
(Cordenonsi et al., 2007). We thus investigated whether a similar
mechanism operated on mutant-p53. In breast MDA-MB-231
cells, endogenous oncogenic Ras is indeed required for
mutant-p53 N-terminal phosphorylation (Figure S5A) and the
formation of the TGFb-induced ternary complex is inhibited by
loss of Ras/MEK signaling or CK13/d depletion (Figures 4E and
S5B). Consistently, as shown in Figure S5C, mutation of the
Ras/CK1-targeted phosphorylation sites of mutant-p53 abol-
ished ternary complex formation in reconstituted H1299 cells
(expressing oncogenic N-Ras, Table S1). In line with these
biochemical data, Ras/CK13d signaling is required for TGFb
induced migration of MDA-MB-231 cells (Figure 4F) and
p53R175H-reconstituted H1299 cells (Figure S5D). We finallyCell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc. 91
Figure 4. TGFb and Ras Signaling Promote
the Assembly of a Mutant-p53/Smad2/p63
Complex
(A) Co-immunoprecipitation/Western blot analysis
of HACAT cell lysates showing endogenous p63
bound to mutant-p53 Cells were left untreated
(lane 2) or treated for 1 hr either with 5 mM
SB431542 (lane 1) or with TGFb1 (5 ng/ml, lanes
3–5). Cells were transfected with anti-Smad2/3
(lane 4) or anti-p53 (lane 5) siRNAs two days before
TGFb treatment. The amount of p63 protein bound
to mutant-p53 is shown as percentage relative to
the amount of total p63 in the inputs.
(B) Western blot analysis of endogenous proteins:
p63 and mutant-p53 coimmunoprecipitated with
Smad2 from HACAT cell lysates.
(C) Mutant-p53 immunopurification from null or
p53R172H knockin MEFs reveals the formation
of a TGFb- and Ras- dependent muant-p53/
Smad/p63 endogenous ternary complex. Cells
were transduced with empty vector (-) or
G12V-HRas (+) and treatedwith the TGFb receptor
inhibitor SB431542 (SB) or with TGFb1 (5 ng/ml).
(D) Transwell migration assays of MEFs with the
indicated genotypes (as in C). Data are repre-
sented as mean and SD.
(E) RAS signaling enables ternary complex forma-
tion in MDA-MB-231 cells. Panels show Western
blot analysis of p53 immunocomplexes from
lysates of MDA-MB-231 left untreated (lane 1) or
incubated for 1 hr with TGFb1 (5 ng/ml) (lanes
2–5). p63 and Smad2 copurify with mutant-p53 in
a TGFb dependent manner (lanes 1 and 2).
Mutant-p53 interaction with p63 is disrupted in
cells depleted of Smad2 and Smad3 (lane 3) or
when mutant-p53/Smad interaction is impaired by
inhibiting the RAS pathway with PD98059 (lane 4).
As specificity control, immunoprecipitations were
carried out from p53-depleted cells (lane 5).
(F) The RAS/MEK/CK13d signaling pathway is
required forTGFb inducedcellmigration.Thegraph
shows number of MDA-MB-231 cells migrated in
a transwell assay. Cell migration in response to
TGFb1 is impairedby treatmentwith theMEK inhib-
itor PD98059 (60 mM) or by transfection with anti-
CK13/d siRNAs. Data are represented as mean
and SD. Similar results were obtained by treating
cells with the CK13/d small molecule inhibitor IC-
261 (data not shown, Cordenonsi et al., 2007).
(G) Lung colonization after tail vein injection of control and CK13/d-depletedMDA-MB-231 cells (n = 10, 33 105 cells/mouse). Depletion was confirmed by western
blotting (Figure S6). Data are represented as mean and SD.validated in vivo the role of CK13/d and found that CK13/
d-depleted MDA-MB-231 failed to undergo metastatic spread
after tail vein injection in recipient mice (Figure 4G).
Together, data presented so far indicate that Ras/CK1
signaling enables ternary complex formation and empowers
TGFb-induced migration and breast cancer cell metastasis.
A Smad Bridge Allows Mutant-p53 to Oppose p63
Our evidences suggest that Smads serve as a critical bridge for
the formation of an inhibitory complex between mutant-p53 and
p63. Using immobilized GST-Smad3 and in vitro translated p63,
we found that their interaction is direct (Figure 5A). Using
different p63 isoforms, we dissected two independent Smad92 Cell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc.interaction surfaces in p63: the p63 N-terminal TA-domain
contacts the MH1 domain of Smad3 whereas the p63 C-terminal
alpha domain binds the Smad3-MH2 domain. While mapping
Smad interaction in the TA domain confirms previous findings
with p53 (Cordenonsi et al., 2007), the identification of a second
Smad interaction surface in the alpha domain of p63 is inter-
esting, first, because this domain has no structural counterparts
in p53 and, second, because the vast majority of p63 is
expressed in vivo as DNa isoform, lacking its TA-domain
(Deyoung and Ellisen, 2007). These structural hints suggest
that RSmad, by mean its N- and C-terminal domains may serve
as a platform to assemble the mutant-p53/p63 complex (Fig-
ure 5B). This configuration might enable mutant-p53 to inhibit
p63 transcriptional properties. To validate this hypothesis, we
monitored p63 transcriptional activity in luciferase assays. p63
overexpression in H1299 cells potently induced transcription
from the p53/p63 element of the Mix.2 promoter (p53BE-lux)
(Figure S8A). Cotransfection of several distinct mutant-p53
isoforms effectively inhibited p63 activity only in cells stimulated
by TGFb/Smad signaling (Figures 5C and S8B).
To better dissect the molecular mechanism of p63 repression
we carried out ChIP analyses on the established p63 binding
elements of the CDKN1A promoter (Deyoung and Ellisen,
2007). As shown in Figure 5D, binding of p63 to its cognate sites
is quantitatively inhibited by mutant-p53 only in the presence of
TGFb signaling (lane 4). Similar results were obtained using
transfected p53BE-lux reporter. Thus, incorporation of p63 into
a TGFb-induced ternary complex impairs p63 binding to DNA.
p63 Titration by Mutant-p53 and Smad Regulates
Metastasis
During malignant progression, sequential elevations of TGFb/
Smad signaling is associated with the acquisition of metastatic
Figure 5. Smad Bridges Mutant-p53 to p63
Inhibition
(A) Panels show the summary of GST-pull down
experiments using immobilized full-length Smad3
(Smad3 FL), Smad3-MH1-linker (Smad3 MH1) or
Smad3-MH2-linker (Smad3 MH2) domains and
in vitro translated p63 variants. We tested p63
isoforms corresponding to natural variants of this
protein, bearing different domains at the N- and
C terminus, as shown in the schematic represen-
tations of these molecules. See Figure S7 for raw
data.
(B) Model for the ternary complex between
DNp63a, Smad2 and mutant-p53.
(C) TGFb signaling empowers the inhibition of p63
transcriptional activity by mutant-p53. H1299 null
cells were transiently transfected with the
p53BE-lux reporter and indicated p53/p63
expression vectors. Graphs show inhibition of
the luciferase activity in cells cotransfected with
p63 and hp53R175H or hp53R273H plasmids,
coding for two distinct hot-spot mutant-p53
alleles. Wild-type p53 is uneffective. Data are rep-
resented as mean and SD. Importantly, additional
mutations of p53 were tested with consistent
results (Figure S8B).
(D) ChIP analysis of p63 bound to its cognate
responsive elements of the endogenous CDKN1A
promoter and transfected recombinant p53-BE-
lux. H1299 cells were transfected with p63,
mutant-p53 or constitutive-active TGFb receptor
expression vectors (TGFb), as indicated. IgG in
lane 1 are irrelevant total rabbit immunoglobulins,
used as background control. p63 Western blotting
ensures comparable pull-downs.
potential (Cui et al., 1996; Oft et al.,
2002). We thus explored the possibility
that the metastatic shift of cancer cells
could correspond to a quantitative inacti-
vation of p63. For this, we monitored the dynamic of the trimeric
complex in locally invasive D3 spindle carcinoma cells and their
metastatic derivative D3S2, bearing constitutive Smad activity
but expressing equal levels of p63, mutant-p53 (p53C236F)
and oncogenic Ras (Oft et al., 2002; Table S1 and Figure 6A).
Cell lysates were immunoprecipitated with anti-p53 antibodies
and coprecipitating p63 quantified by Western blotting. The
amount of p63 complexed by mutant-p53 raised dramatically
upon TGFb treatment in D3 cells (becoming 50% of the input),
to become essentially quantitative (>95%) in metastatic D3S2
cells (Figures 6B and 6C). Thus, in advanced tumors, increasing
doses of TGFb/Smad2 signaling correspond to increasing levels
of p63 trapped into mutant-p53-containing complexes.
D3S2 cells allow to validate in vivo the requirement of mutant-
p53 and oncogenic Ras/CK1 signaling in a cellular context
rendered metastatic by elevated Smad signaling (Figure S9A).
As shown in Figure 6D, mutant-p53, high levels of oncogenic
Ras and CK13/d activity are required for lung metastasis of
D3S2 cells upon tail vein injection in immunocompromised
mice. This closely recapitulates our previous findings in humanCell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc. 93
Figure 6. p63 Titration by Mutant-p53 and Smad
Regulates Metastasis
(A) Western blot analysis of spindle cells D3 and their meta-
static derivative D3S2 cells for Smad2, p63 and mutant-p53.
p63 is detected after immunoprecipitation.
(B) Coimmunoprecipitation of p63 with mutant-p53 from D3
and D3S2 cell lysates. Increases in TGFb signaling parallels
with increasing incorporation of free p63 into ternary
complexes (lanes 1-3). Complex formation is disabled after
Smad2/3 knockdown.
(C) To quantify the fraction of free-p63 in the D3 series, we
immunoprecipitated mutant-p53 and then quantified associ-
ated p63 byWestern blot and finally compared this quantifica-
tion to that one of the total p63 of the corresponding extract.
The graph in the y axis indicated the remaining free p63.
(D and E) Lung colonization assay of control and mutant-p53-,
CK13/d- and HRas-depleted D3S2 cells after tail vein injection
in SCID mice (n = 8–12 for each depleted cell population,
2 3 105 cells/mouse). See Figure S9C for representative
photos of the corresponding lungs 25 days post-injection.
Data are represented as mean and SD. When injected
subcutaneously, control and siRNA-depleted cell population
displayed comparable growth-rates (Figure S9B). (E) Panels
show the corresponding immunoblotting.
(F–H) D3S2 or D3S2-p63 cells were injected as in (D) (n = 10 for
each line, 2 3 105 cells/mouse). (F) Number of metastatic
nodules in the lungs. Data are represented as mean and SD
(G and H) Representative hematoxylin and eosin staining of
lung sections from mice injected with D3S2 and D3S2-p63
cells; M, metastatic nodule.breast cancer cells, suggesting a general impact for the mecha-
nism here described in TGFb-driven malignancy.
Further challenging themutant-p53/p63 axis, we also tested in
D3S2whether tipping back the balance by raising p63 levels was
sufficient to confer metastasis-protection. For this, we stably
transduced D3S2 with DNp63a expression construct (D3S2-
p63), andmonitored lung colonization upon intravenous injection
in recipient mice. D3S2-p63 cells displayed a remarkably weaker
metastatic potential when compared to parental D3S2 (Figures
6F–6H). Notably, p63 expression did not impair tumor growth
per se (Figure S9D). Thus, rebalancing the mutant-p53/p63 ratio
specifically inhibits metastatic proclivity, underlining how even
advanced cancer cells retain exquisite sensitivity to p63 activity.
A New Class of TGFb Gene Responses
We next sought to investigate the specific gene expression
program by which mutant-p53 and TGFb control invasion and
metastasis in breast cancer, for which a rich set of patients’ data-
bases with molecular profiles and associated clinical history is
available.
We first compared the TGFb transcriptomic profile of control
and mutant-p53 depleted MDA-MB-231 cells. We found that
TGFb orchestrates the expression of a mutant-p53-independent
genetic program entailing a large fraction of genes previously
implicated in cell movement, invasion or metastasis (Figure 7A
and Table S2); and yet, the phenotypic exploitation of this94 Cell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc.complex program occurs only in the presence of mutant-p53
(Figure 7B).
We therefore focused our attention to themuchmore restricted
set of genes co-regulated by mutant-p53 and TGFb; strikingly
indeed, this entailed only five genes: Sharp-1/DEC2/BHLHB3,
Cyclin G2/CCNG2, ADAMTS9, Follistatin, and GPR87 (see table
and northern blots in Figure S10). In particular, we focused on
two, so far poorly characterized genes, Sharp-1 and Cyclin G2,
that are negatively regulated by TGFb via mutant-p53: this
suggested a role asmetastasis suppressors (Figure 7C). To verify
these molecules as positive targets of p63, control and p63
siRNA-depleted MDA-MB-231 cells were assayed for gene
expressionbyquantitativeRT-PCR.Lossof p63potently inhibited
the expression of Sharp-1 and Cyclin G2, an effect phenocopied
by TGFb treatment in control cells (Figure 7D). Of note, TGFb
had no effect in p63 knockdown cells, suggesting that TGFb has
no additional, p63-independent, repressing effects on these
genes.
Little is known on the transcriptional regulation of Sharp-1 or
Cyclin G2. By means of ChIP, we identified in the Cyclin G2
genomic region a binding element for endogenous p63 (Fig-
ure S11). In keeping with the requirement of mutant-p53 for
TGFb-mediated repression of these genes, we found that TGFb
antagonizes p63 recruitment to theCyclin G2 promoter in control
MDA-MB-231 cells (Figure 7E, lanes 2 and 3) but failed to do so
after mutant-p53 depletion (lanes 4 and 5).
Figure 7. Identification and Clinical Valida-
tion of Candidate Metastasis Suppressors
Downstream of the TGFb /Mutant-p53/p63
Axis
(A) Overview of TGFb target genes from microar-
ray analysis of MDA-MB-231 cells. The graph
shows functional classification for genes regulated
by TGFb in both MDA shGFP and MDA shp53 cell
lines. Many genes codes for protein involved in cell
invasion, migration and metastasis (‘‘invasive
program,’’ see Table S2).
(B) Schematic representation of the dual role for
TGFb in promoting metastasis. TGFb activates
an invasive program independently of mutant-
p53 expression. p63 restrains the deployment of
this program by inducing metastasis suppressor
genes. In mutant-p53 expressing cells, TGFb can
overcome this block by inactivating p63 through
the mutant-p53/Smad2 axis.
(C) Regulation of Sharp-1 and Cyclin G2 expres-
sion by TGFb and mutant-p53 in MDA-MB-231
cells. Northern blot analysis of MDA shGFP and
MDA shp53 cells untreated or treated for two
hours with TGFb1 (5 ng/ml). GAPDH is a loading
control. Both genes are downregulated by TGFb
in parental cells but not after mutant-p53 knock-
down.
(D) Sharp-1 and Cyclin G2 are targets of endoge-
nous p63 in MDA-MB-231 cells. Graphs show
Sharp-1 and Cyclin G2 mRNA expression moni-
tored byQ-PCR from cells transfectedwith control
or anti-p63 siRNAs.
(E) ChIP analysis of endogenous p63 bound to its
binding element in Cyclin G2. Lane 1 is a negative
control ChIP carried out with aspecific rabbit IgG.
(F) The impairment of TGFb-driven migration of
mutant-p53 depleted cells in transwell assays
can be rescued by concomitant depletion of
Sharp-1 or Cyclin G2. Data are represented as
mean and SD. For controls of effectiveness of
independent siRNA sequences and knockdowns,
see Figure S12.
(G, H and I) Analysis of the predictive power of the
minimal signature (Sharp-1 + Cyclin G2).
(G) Statistical analysis of Sharp-1 and Cyclin G2
expression from the Stockholm dataset (including
genomic data and matched clinical history for
156 patients). The analysis separates tumor
samples in two groups, with coherent low or high
expression of both genes, as visualized by box-
plot graphs. ‘‘Low’’ and ‘‘High’’ are the names of
the two groups of patients. Each box represents
median and 75th and 25th percentile values.
(H) Kaplan-Meier graphs representing the proba-
bility of cumulative recurrence-free survival in
breast cancer patients from the Stockholm dataset stratified according theminimal signature. The log-rank test p value reflects the significance of the association
between minimal signature ‘‘High’’ and longer survival.
(I) Kaplan-Meier curves showing the recurrence free-survival for patients from the Stockholm dataset stratified according the Nottingham histological scale
(grade 1 dotted line; grade 2, violet line; and grade 3, dashed line). Grade 2 tumors were further split in two groups by applying the minimal signature
(red line: grade 2 and minimal signature high; blue line: grade 2 and minimal signature low). Notably, the ‘‘High’’ and ‘‘Low’’ groups displayed a recurrence-
free survival rate similar to the grade 1 or grade 3 patients, respectively.To functionally validate these genes as effectors of themutant-
p53/Smad/p63 pathway, we carried out epistasis experiments
testing if depletion of Sharp-1 or Cyclin G2 could rescue TGFbinduced migration in p53-depleted cells. As shown in Figure 7F,
siRNA-mediated knockdowns of Sharp-1 or Cyclin G2 restore
TGFb dependent promigratory activities in shp53MDA-MB-231,Cell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc. 95
phenocopying p63-depletion. Thus, these molecules mediate
the antagonizing effect of p63 on TGFb proinvasive responses.
Clinical Validation of Sharp-1 and Cyclin G2
Having identified genes essential to antagonize invasive
behavior in vitro, we then sought to elucidate their clinical
relevance as metastasis suppressors. Recent transcriptomic
profilings of primary human tumors have identified gene suites,
or ‘‘signatures,’’ that predict high risk of metastasis and poor
disease-free survival (Fan et al., 2006). If the detection of
Sharp-1 andCyclin G2 in primary tumors is biologically meaning-
ful, one might expect that reduced expression of these genes
should be associated with poor clinical outcome. Of note,
Sharp-1 and Cyclin G2 are not contained in known signatures
for breast cancer metastasis, i.e., the ‘‘70-genes signature,’’
the ‘‘recurrence score’’ or others (Fan et al., 2006).
To evaluate the prognostic value of Sharp-1 and Cyclin G2
(henceforth ‘‘minimal signature’’), we took advantage of the avail-
able gene expression datasets summing up to 1200 primary
breast cancers with associated clinical data, including survival
and distant recurrence (Table S7). We defined in each dataset
two groups of tumors with respectively high and low level of
expression of Sharp-1 and Cyclin G2 (Figures 7G, S13, and
S14) (see Experimental Procedures for statistical analyses).
Strikingly, when tested using the univariate Kaplan-Meier survival
analysis, the group expressing low levels of theminimal signature
(‘‘Low’’) displayed a significant higher probability to develop
recurrencewhen compared to the ‘‘High’’ group (p values ranged
from 0.02 to 3E-05, depending on the datasets) (Figures 7H, S13
and S14). Interestingly, the minimal signature performed compa-
rably to the 70-genes profile in stratifying patients according to
their clinical outcome (Figure S13) and is associated to risk of
distant metastasis to both bone and lung (Figure S15).
To further evaluate the prognostic value of the minimal signa-
ture we performed multivariate Cox proportional-hazards
analysis on the 187 tumors dataset from National Cancer
Institute and 295 tumors from the NKI database (Fan et al.,
2006; Sotiriou et al., 2006). With these cohorts, we could eval-
uate the minimal signature in the context of some variables
commonly used in the clinical practice, such as estrogen-
receptor status, tumor diameter, nodal status, tumor grade and
treatment status. The minimal signature remained a significant
predictor of metastasis-free survival (Tables S3 and S4). Further-
more, the minimal signature is an independent predictor of
survival that adds new prognostic information to established
clinical predictors such as size, node status, tumor grade, ER
status, age and treatment (Figures S16 and S17). A point in
case are tumors classified as intermediate (grade 2) by the
Nottingham scale, that represent the majority of tumors and
whose prognosis is uncertain (Ivshina et al., 2006). When applied
to grade 2 tumors of multiple independent datasets, the minimal
signature resolved these patients into two groups with outcomes
comparable to grade 1 (good prognosis) and grade 3 (bad prog-
nosis), respectively (Figure 7I and S18).
In sum, the clinical validation as prognostic tool of Cyclin G2
and Sharp-1, two targets of the TGFb/mutant-p53/p63 axis,
supports the general relevance of the mechanisms here
described for breast cancer metastasis.96 Cell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc.DISCUSSION
A TGFb/Mutant-p53 Pathway for Metastasis
Here, we describe a signaling pathway that instills metastatic
proclivity to epithelial cancer cells: TGFb –> Smad/mutant-
p53–j p63–j metastasis.
In this model, gain-of-TGFb metastatic properties can be
acquired by the combined action of two common oncogenic
lesions, Ras and p53-mutation. Gain of mutant-p53 expression
in noninvasive tumor cells empowers TGFb proinvasive and
migratory abilities, whereas loss of mutant-p53 expression in
aggressive tumors impairs their metastagenicity.
A wealth of published data documented the requirement of
Ras for TGFb malignant responses but the mechanism of such
interplay has not been addressed (Grunert et al., 2003). Our
data provide a step forward in this direction: Ras signaling
promotes mutant-p53 phosphorylation and, in so doing, it is
required for the formation of the mutant-p53/Smad complex.
The critical role of mutant-p53 in metastasis has been recently
suggested from elegant studies in transgenic mice, and this is
particularly striking when expression of mutant-p53 is combined
with oncogenic Ras (Caulin et al., 2007; Hingorani et al., 2005). In
humans, p53 mutations are associated to poor prognosis in
several types of tumors; intriguingly, p53-mutation is selected
at very high frequency in aggressive HER-2 positive and basal-
like breast cancers, that are particularly prone to metastasize
(Sorlie et al., 2001).
How and when a tumor acquires metastatic properties is
unknown (Bernards and Weinberg, 2002). Here we propose that
mutations in the p53 and Ras pathways, selected to promote
growth and survival of early neoplasms, also prefigure a cellular
set-up with particular metastasis proclivity. This ‘‘passenger’’
trait will be exploited later on, during progression, to drive the
metastatic switch, once cells gain access to high levels of
TGFb, either autonomously produced or extracted from the
microenvironment.
p63 Opposes TGFb-Induced Metastasis
We show a primary role for the p53 family member p63 as
antagonist of TGFb driven tumor invasiveness and metastasis.
p63 is highly expressed in basal cells of stratified epithelia;
however, its role during tumorigenesis is unclear (Deyoung
and Ellisen, 2007). Here we show that functional inactivation
of p63 by the TGFb induced mutant-p53/Smad complex is crit-
ical for gain of metastatic proclivity. Mutant-p53 and Smad
intercept p63 to form a ternary complex, in which the p63 tran-
scriptional functions are antagonized. Thus, in presence of
mutant-p53, TGFb attains control over p63. This unleashes
TGFb malignant effects. Indeed, mutant-p53 knockdown in
metastatic cancer cells does not affect the expression of the
TGFb invasive program but rather forestalls its phenotypic
exploitation. As expected from p63 being downstream of
mutant-p53, inactivation of p63 transforms non-invasive cells
into malignant tumors and rescues metastasis ability in mutant-
p53-depleted breast cancer cells. Moreover, the quantal
increase of Smad signaling that renders metastatic D3 carci-
noma cells coincides with a quantitative loss of ‘‘free,’’ uncom-
plexed p63. Strikingly, tipping back the balance by adding
extra-p63 in these cells is sufficient to prevent such TGFb-
induced metastatic spread.
We previously showed that p53 family members and Smads
cooperate for mesoderm development in Xenopus embryos
and for growth arrest in mammalian cells, acting through
independent binding elements in jointly-regulated promoters
(Cordenonsi et al., 2003, 2007). Here we show that in metastatic
cells p63 and TGFb also play antagonistic functions. Indeed, in
this context, Smads are not operating as transcription factors,
but as adapters, bridging together mutant-p53 and p63.
What may then determine the predominance of tumor
suppressive versus promalignant responses to TGFb? We
propose that a crucial determinant is the relative distribution of
p63 into three pools: free, bound to Smad2 in transcriptionally
cooperating complexes, or instead inactivated into mutant-
p53/Smad2 ternary complexes. Mutation of p53, the levels of
Ras and p63, as well as the strength of TGFb signaling, are
critical variables in p63 distribution. During tumor progression,
sequential elevations of constitutive Ras and Smad2 activity
would foster a more and more quantitative incorporation of
p63 into ternary complexes. Beside dampening the growth
arrest response, this would progressively titrate away the anti-
metastatic properties of free-p63. Finally, in advanced stages
of the disease, quantitative inactivation of p63 would finally
unleash TGFb-driven metastasis.
In this paper, we also tackled the issue of how p63 inhibits
metastasis. We identified two genes, Sharp1 and Cyclin G2,
that are downstream of the TGFb/mutant-p53/p63 pathway.
These were functionally validated in vitro as essential mediators
of p63-mediated antagonism toward TGFb responses. Tradi-
tional prognostic markers are able to confidentially assign prog-
nosis to less than 50% of breast cancer patients. For the rest of
the patients, new prognostic tools are required to assess the risk
of metastasis and thus identify those that would benefit from
adjuvant treatments. Strikingly, in cancer patients, expression
of Sharp-1 and Cyclin G2 represents a ‘‘minimal signature’’
with prognostic value independent from currently used clinical
and histopathological variables. In spite of its simplicity, the
minimal signature has predictive power comparable to more
complex gene sets of predictors (Figure S13).
The mechanisms by which Sharp-1 and Cyclin G2 may act as
metastasis suppressors in vivo remain ground for future studies.
In the meantime, their use as diagnostic tools should be imple-
mented for patients’ stratification in the clinical laboratory.
EXPERIMENTAL PROCEDURES
Additional methods can be found in the Supplemental Data.
Transfections and Retroviral Infections
For siRNA transfection, dsRNA oligos (10 picomoles/cm2) were transfected
using the RNAi Max reagent (Invitrogen). A complete list of siRNAs is provided
in Table S5. For transient overexpression studies, p63 expression vectors
(0.4 mg/cm2) were transfected in MDA-MB-231 using LT1 reagent (MIRUS).
Wild-type and mutant-p53 expression constructs (7.5 ng/cm2) were trans-
fected in H1299 cells with Lipofectamine 2000 (Invitrogen).
Stable shRNA-expressing MDA-MB-231 cells were obtained by infection
with pSuperRetro plasmids containing the interfering sequence (sh) indicated
in Table S5 (as described in Dupont et al., 2009). Lentiviral vectors coding forwild-type-p53, mutant-p53 or p63DD were transfected in 293 cells in
combination with pMDG and pCMV8.74 to obtain viral particles used to infect
mutant-p53 depleted MDA-MB-231. D3S2-p63 were obtained by retroviral
infection of D3S2 with pBABE-DNp63a. B9-p63DD and B9-GFP were ob-
tained by retroviral delivery of p63DD-expressing or empty vector, respec-
tively. Cells were drug selected to enrich for positive transfectants. MEFs
were infected with a retroviral vector containing activated H-RasG12V cDNA
and puromycin resistance as described in Lang et al., 2004.
Migration and Invasion Assays
For wound-closure experiments, H1299 cells were plated in 6-well plates and
cultured to confluence. Cells were scraped with a p200 tip (time 0), transferred
to low serum and treated as described. Number of migrating cells were
counted from pictures (five fields) taken at the indicated time points.
Transwell assay were performed in 24 well PET inserts (Falcon 8.0 mm pore
size) for migration assays and in Matrigel-GFR coated PET inserts (Falcon) for
invasion assays. For MDA-MB-231, cells were plated in 10 cm dishes, trans-
fected with siRNA or DNA plasmids and, after 8 hr, serum starved overnight.
Then, 50000 or 100000 cells were plated in transwell inserts (at least 3 replicas
for each sample) and either left untreated, treated with SB431542 (5 mM) or
TGFb1 (5 ng/ml). For H1299, cells were plated in the transwell in 10% serum
but then changed to 0.2% serum. Cells in the upper part of the transwells
were removed with a cotton swab; migrated cells were fixed in PFA 4% and
stained with Crystal Violet 0.5%. Filters were photographed and the total
number of cells counted. Every experiment was repeated at least three times
independently.
For matrigel invasion assay shown in Figure S2C, MDA-MB-231 and deriv-
ative cell lines were resuspended in drops (100 ml) of Matrigel Growth Factor
Reduced (BD Biosciences), diluted 1:2 in DMEM/F12.
In Vivo Metastasis Assays
Mice were housed in Specific Pathogen Free (SPF) animal facilities and treated
in conformity with approved institutional guidelines (U.Padua and UCSF). For
xenograft studies of breast cancer metastasis, shGFP- or shp53-MDA-MB-
231 cells (1 X 106 cells/mouse) were unilaterally injected into the mammary
fat pad of SCID female mice, age-matched between 5 and 7 weeks. After
six weeks, mice were sacrificed and examined for metastases to lymph nodes.
Macroscopic metastases to other organs were infrequent (liver, lung, perito-
neum). Tumor growth in the injected site was monitored by repeated caliper
measurements. For lung colonization assays, cells were resuspended in
100 ml of PBS and inoculated in the tail vein of SCID mice. Four weeks later,
animals were sacrificed and lungs removed for the subsequent histological
analysis. D3S2 and D3S2-p63 were also inoculated subcutaneously to
evaluate the growth rate. The procedure for subcutaneous injection of mouse
B9 squamous cancer cells was as previously described (Oft et al., 2002). For
counting the total number of independent lesions per lung after tail vein injec-
tion, serial sections of the lungs, cut at a distance of 70 mm from each other,
were stained with Hematoxylin and Eosin.
Protein Interaction Studies
To detect endogenous p63/Smad2/mutant-p53 complexes, cells were lysed
by sonication in 20 mM HEPES (pH 7.8), 400 mM KCl, 5% Glycerol, 5 mM
EDTA, 0.4% Np40, phosphatase and protease inhibitors, and cleared by
centrifugation. For immunoprecipitations, extracts were diluted to 20 mM
HEPES (pH 7.8), 50 mM KCl, 5% Glycerol, 2.5 mM MgCl2, 0.05% NP40 and
incubated with the appropriate proteinA-sepharose bound antibodies for
four hours at 4C. Prior to IP, beads were incubated overnight in PBS with
2% BSA and 0.05% CHAPS. After three washes in binding buffer, copurified
proteins were analyzed by immunoblotting by using as secondary antibodies
the ExactaCruz reagents (Santa Cruz biotechnology) to reduce the back-
ground from IgG. The amount of coprecipitated p63 was determined by
quantification of western blots using ImageJ (NIH). PAB421 monoclonal
antibody (Calbiochem) was used for p53 immunoprecipitations. For Smad2
IPs, we used the anti-Smad2 polyclonal antibodies (S-20, Santa Cruz biotech-
nology). The procedure for GST-pull-down assays was described in Corde-
nonsi et al., 2003.Cell 137, 87–98, April 3, 2009 ª2009 Elsevier Inc. 97
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